Education
About Us
Working with TipRanks
Follow Us
Cidara Therapeutics (CDTX)
NASDAQ:CDTX
Total Valuation
Cidara Therapeutics has a market cap or net worth of $327.10M. The enterprise value is $161.62M.
Market Cap$327.10M
Enterprise Value$161.62M
Share Statistics
Cidara Therapeutics has 12,969,823 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,969,823
Owned by Insiders18.54%
Owned by Institutions25.96%
Financial Efficiency
Cidara Therapeutics’s return on equity (ROE) is -1.04 and return on invested capital (ROIC) is -105.52%.
Return on Equity (ROE)-1.04
Return on Assets (ROA)-0.79
Return on Invested Capital (ROIC)-105.52%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee33.55K
Profits Per Employee-4.47M
Employee Count38
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cidara Therapeutics is -1.01. Cidara Therapeutics’s PEG ratio is -0.95.
PE Ratio-1.01
PS Ratio0.00
PB Ratio2.52
Price to Fair Value1.05
Price to FCF-1.70
Price to Operating Cash Flow-1.86
PEG Ratio-0.95
Income Statement
In the last 12 months, Cidara Therapeutics had revenue of 1.27M and earned -169.83M in profits. Earnings per share was -26.75.
Revenue1.27M
Gross Profit1.04M
Operating Income-176.10M
Pretax Income-170.29M
Net Income-169.83M
EBITDA-176.10M
Earnings Per Share (EPS)-26.75
Cash Flow
In the last 12 months, operating cash flow was -191.84M and capital expenditures -106.00K, giving a free cash flow of -191.94M billion.
Operating Cash Flow-191.84M
Free Cash Flow-191.94M
Free Cash Flow per Share-14.80
Dividends & Yields
Cidara Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.62
52-Week Price Change87.79%
50-Day Moving Average21.13
200-Day Moving Average18.53
Relative Strength Index (RSI)61.88
Average Volume (3m)154.23K
Important Dates
Cidara Therapeutics upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
Cidara Therapeutics as a current ratio of 4.25, with Debt / Equity ratio of 1.89%
Current Ratio4.25
Quick Ratio4.25
Debt to Market Cap<0.01
Net Debt to EBITDA1.06
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cidara Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cidara Therapeutics EV to EBITDA ratio is 0.09, with an EV/FCF ratio of 0.09.
EV to Sales-12.21
EV to EBITDA0.09
EV to Free Cash Flow0.09
EV to Operating Cash Flow0.09
Balance Sheet
Cidara Therapeutics has $168.15M in cash and marketable securities with $2.67M in debt, giving a net cash position of -$165.48M billion.
Cash & Marketable Securities$168.15M
Total Debt$2.67M
Net Cash-$165.48M
Net Cash Per Share-$12.76
Tangible Book Value Per Share$25.72
Margins
Gross margin is 81.13%, with operating margin of -13811.92%, and net profit margin of -13319.76%.
Gross Margin81.13%
Operating Margin-13811.92%
Pretax Margin-13356.16%
Net Profit Margin-13319.76%
EBITDA Margin-13811.92%
EBIT Margin-13811.92%
Analyst Forecast
The average price target for Cidara Therapeutics is $41.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.33
Price Target Upside63.88% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-99.35%
EPS Growth Forecast-260.33%